| Manufacturer || Teva Pharmaceuticals
| Disease || Huntington's Disease / Tardive Dyskinesia
| Indication || Chorea associated with Huntington’s disease; Tardive dyskinesia
| Mode of Action || Vesicular monoamine transporter 2 (VMAT2) inhibitor
| Approval Status || FDA approved (USA)
| Strength || 6 mg, 12 mg, 9 mg
Who is deutetrabenazine for?
Austedo (deutetrabenazine) is indicated for the treatment of patients with chorea associated with Huntington’s disease 
. Chorea is a disorder characterised by brief, abrupt, irregular, unpredictable, non-stereotyped movements which can affect various body parts and interfere with speech, swallowing, posture and gait 
Austedo is approved also for the treatment of adults with tardive dyskinesia 
, a debilitating and often irreversible movement disorder characterised by repetitive and uncontrollable movements of the tongue, lips, face, trunk, and extremities 
Complete information about Austedo (deutetrabenazine) dosage and administration can be found here: 
The dose of Austedo (deutetrabenazine) is determined for each patient based on the reduction of chorea or tardive dyskinesia, and tolerability 
The recommended starting dose of Austedo is 6 mg administered orally once daily for patients with Huntington’s disease and 12 mg per day (6 mg twice daily) for patients with tardive dyskinesia. The dosage has to be adjusted according to the patient's treatment history.Patients who are not switching from tetrabenazine
When prescribed to patients who are not being switched from tetrabenazine (a related VMAT2 inhibitor):
Patients who are switching from tetrabenazine
- increase the dose at weekly intervals in increments of 6 mg per day to a maximum recommended daily dosage of 48 mg
- total daily dosages of 12 mg or above should be administered in two divided doses
- administer with food and swallow whole. Do not chew, crush, or break tablets .
Patients who are taking tetrabenazine and are switching to Austedo (deutetrabenazine) should discontinue tetrabenazine and initiate Austedo the following day. The recommended initial dosing depends on the current tetrabenazine daily dosage. Detailed information can be found on the FDA official prescribing information on page 2 
.Consult your doctor for personalised dosage.Warning
Austedo (deutetrabenazine) can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease. Anyone considering the use of Austedo (deutetrabenazine) must balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician 
What is deutetrabenazine and how does it work?
Austedo (deutetrabenazine) is a medicine used to treat adults with chorea associated with Huntington’s disease and tardive dyskinesia 
- Chorea is a disorder characterised by brief, abrupt, irregular, unpredictable, non-stereotyped movements which can affect various body parts, and interfere with speech, swallowing, posture and gait 
- Tardive dyskinesia is a debilitating and often irreversible movement disorder characterised by repetitive and uncontrollable movements of the tongue, lips, face, trunk, and extremities. It can be caused by certain medications used to treat mental health conditions or gastrointestinal conditions .
Austedo is a vesicular monoamine transporter 2 (VMAT2) inhibitor 
. A VMAT2 is a protein essential for the release of neurotransmitters into the synaptic cleft — the space between neurons where the communication between neurons takes place 
. The precise mechanism by which Austedo (deutetrabenazine) exerts its anti-chorea effects is unknown but it is expected to clear the nerve terminals from neurotransmitters like dopamine, serotonin, norepinephrine, and histamine. This reversible effect seems to be responsible for reducing chorea and tardive dyskinesia 
Austedo (deutetrabenazine) is the second product approved for the treatment of Huntington’s Disease, the other one being tetrabenazine 
. The two medicines have a very similar mechanism of action. The main difference between the two is that Austedo (deutetrabenazine) is metabolised more slowly and thus enables less frequent and lower daily doses, achieving the same effect whilst lowering the risk of side effects. Compared with tetrabenazine, deutetrabenazine has, thus, an improved risk-benefit profile 
What is deutetrabenazine's approval status?
Austedo (deutetrabenazine) was approved by:
for the treatment of chorea associated with Huntington’s disease . On August 30, 2017, the FDA extended the approval to the treatment of tardive dyskinesia .The efficacy of Austedo (deutetrabenazine) in the treatment of chorea associated with Huntington's disease was established in a trial that compared Austedo (deutetrabenazine) with placebo (a substance with no therapeutic effect). The study involved 90 patients with manifest chorea associated with Huntington’s disease but with maintained walking ability .The study lasted 13 weeks – 12 weeks of treatment and 1 final week of treatment interruption (washout). The 12 weeks of treatment consisted of 8 weeks of gradual dosage increase (titration) and 4 weeks of maintenance .The initial dose for patients on Austedo (deutetrabenazine) was 6 mg per day and it was incremented at weekly intervals with increments of 6 mg until satisfactory treatment of chorea was achieved, intolerable side effects occurred, or until a maximal dose of 48 mg per day was reached .The two patient groups (placebo and deutetrabenazine) were compared on the basis of the scores achieved on different scales. The most important measure was the change in the total maximal chorea score from the beginning of the study (baseline). The total maximal chorea score ranges from 0 to 28, where a lower score indicates less chorea. It is given by the sum of maximal chorea scores for 7 body regions (face, buccal-oral-lingual, trunk, and 4 extremities), each of which is scored on a scale from 0 to 4 (0 = absent; 1 = slight or intermittent; 2 = mild and common or moderate and intermittent; 3 = moderate and common; and 4 = marked and prolonged). Among the other scales used to monitor the patients were the Patient Global Impression of Change (PGIC), Clinical Global Impression of Change (CGIC), the 36-Item Short Form Health Survey (SF-36) physical functioning subscale score, and Berg Balance Test. The PGIC and CGIC are scales designed to assess the effects of treatment as perceived by patients and clinicians, respectively. The SF36 is a survey on patient health, and the Berg Balance Test is a clinical test of a person's static and dynamic balance abilities .Austedo resulted better than placebo in all tests except the Berg Balance Test. The difference in improvement in total maximal chorea score between the two groups was significantly in favour of Austedo (deutetrabenazine): patients in the deutetrabenazine group had a mean of –4.4 (95 % CI, –5.3 to –3.6) improvement in total maximal chorea score, whereas the placebo group improved by –1.9 (95 % CI, –2.8 to –1.1). Following the treatment interruption (washout), chorea returned to the level it was before the study started .In the deutetrabenazine group 51 % of patients reported treatment success by the PGIC scale versus 20 % in the placebo group. Similarly, 42 % of patients in the deutetrabenazine group reported treatment success using the CGIC scale vs 13 % of patients in the placebo group. The SF-36 physical functioning subscale improved by 0.7 (95 % CI, –2.0 to 3.4) for deutetrabenazine and worsened by –3.6 (95 % CI, –6.4 to –0.8) for the placebo group. There was no significant difference in improvement in Berg Balance Test .There was no difference in the number of adverse events among the two groups overall and within psychiatric and nervous system areas, with serious adverse events in one patient per group . The most common adverse reactions occurring in more than 8 % of Austedo-treated patients were somnolence, diarrhoea, dry mouth, and fatigue .The efficacy of Austedo (deutetrabenazine) in the treatment of tardive dyskinesia was established in 2 X 12 week, randomised, double-blind, placebo-controlled, multicentre trials conducted in 335 adult ambulatory patients with tardive dyskinesia caused by the use of antipsychotics (dopamine receptor antagonists) . The most important measure in both studies was the change in Abnormal Involuntary Movement Scale (AIMS). The AIMS is a 12 item scale for the assessment of tardive dyskinesia severity. The first 7 items assess the severity of involuntary movements across body regions and these items were used in this study .Each of the 7 items was scored on a 0 to 4 scale, with 0 = not present and 4 = severe (abnormal movements occur almost continuously and/or of extreme intensity). The AIMS total score across the 7 considered items could thus range from 0 to 28, with a decrease in score indicating improvement .Study 1 involved 222 patients who were divided into 4 groups: 1 group took placebo and the other 3 took Austedo (deutetrabenazine). The treatment included a 4 weeks dose escalation, 8 weeks of maintenance and 1 final week of treatment interruption (washout). Of those that took Austedo, a first group took 12 mg daily for the whole duration of the study, a second group started with 12 mg daily and increased to 24 mg daily, and a third group started with 12 mg daily up to 36 mg daily. Patients receiving the 24 mg and the 36 mg dose had an improvement in the AIMS score of 3.3 and 3.2 units respectively, compared with 1.4 units in the place group .Study 2 involved 113 patients. It lasted for 12 weeks, during which Austedo was tested against placebo, adjusting the dose from 12 mg with increases allowed in 6 mg increments at 1 week intervals until satisfactory control of dyskinesia was achieved, intolerable side effects occurred, or a maximal dose of 48 mg per day was reached. The AIMS total score for patients receiving Austedo demonstrated a statistically significant improvement of 3.0 units from baseline to endpoint (week 12), compared with 1.6 units in the placebo group .The most common adverse reactions occurring in more than 3 % of Austedo-treated patients, greater than the percentage occurring with placebo patients, were nasopharyngitis and insomnia .
- FDA (USA) on April 3, 2017
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.